Xiangyu Medical Co. Ltd. A

The Ninth Central China Rehabilitation Forum and the Eleventh Rehabilitation Equipment Expo were held in Anyang, Henan. The Brain-Computer Interface Rehabilitation Technology Innovation Consortium, led by Xiangyu Medical, expanded again, with seven medical institutions including the First Affiliated Hospital of Nanchang University officially joining. Xiangyu Medical also established a joint brain-computer interface laboratory with the School of Rehabilitation at Wenzhou Medical University, and signed clinical strategic cooperation agreements with institutions such as Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology. On the international front, Xiangyu Medical signed a strategic cooperation agreement with the team of international expert Professor Guttenbrunner, and two international platforms—the Rehabilitation International-China Cooperation Center and the International Shockwave Training Base—were unveiled. The expo showcased over a thousand smart rehabilitation products, with the brain-computer interface smart care ward taking center stage. This solution uses non-invasive brain-computer interfaces as its core, enabling patients to control ward facilities through thought. Xiangyu Medical has built a brain-computer rehabilitation product matrix covering scenarios such as movement, cognition, speech, and swallowing. Intelligent devices like the infrared light moxibustion robot and lower-limb exoskeleton rehabilitation robot were also on display. At the policy level, brain-computer interfaces have been included in the government work report's list of future industries to cultivate and in the forward-looking layout of key tracks in the 15th Five-Year Plan outline. In 2024, China's brain-computer interface market reached 3.2 billion yuan, up 18.81 percent year-on-year, and is expected to grow to 4.6 billion yuan by 2026. Xiangyu Medical's 2025 annual report shows that R&D spending accounted for as much as 24.65 percent of operating revenue, underpinning its technology reserves.

The Sci-Tech Innovation Board Medical ETF from China Asset Management, ticker 588130, has recorded consecutive net inflows over the past five trading days, drawing a combined 99.31 million yuan, with an average daily net inflow of 19.86 million yuan. As of 11 a.m. on July 28, the ETF was quoted at 0.99 yuan, with intraday turnover of 8.04 percent and trading volume of 36.07 million yuan. The constituent stocks of the Shanghai Sci-Tech Innovation Board Biomedical Index it tracks were mixed, with Xiangyu Medical leading gains at 9.07 percent. In related news, as of July 27, 100 pharmaceutical and biotech companies listed on the A-share market had disclosed their semi-annual earnings forecasts for 2026, of which 64 expected growth in net profit attributable to the parent company, and 26 projected year-on-year growth exceeding 100 percent.

On the morning of July 27, A-share brain-computer interface concept stocks broke out strongly, with stocks in the sector rising collectively during the session. Chuangxin Medical hit a three-day two-board pattern, Aipeng Medical recorded a 20 percent daily limit up, Hainan Haiyao recorded a 10 percent daily limit up and hit a four-day two-board pattern, while Meihao Medical, New Journey, Yingkang Life, Xiangyu Medical, and Sanbo Brain Hospital and other concept stocks followed the rally. On the news front, a Chinese research team recently released a new type of EEG signal acquisition device, achieving for the first time globally the synchronous collection of EEG signals from over a thousand people across different regions. This breakthrough marks a key step forward in neural large model training and general brain-computer interface technology research and development. Kaiyuan Securities stated that it remains bullish on innovative drugs and their industry chain, as well as national strategic emerging industries such as AI, brain-computer interfaces, and biomanufacturing.